Associated Banc-Corp heads into its July 23 Q2 earnings report with the Street turning incrementally more constructive, even as insiders have been quietly trimming into the rally.
The most notable move this week came from the sell side. Raymond James raised its price target on ASB to $35 from $31 this morning, maintaining an Outperform rating — the most bullish call among active coverage. The broader analyst picture has shifted in the same direction over recent months: Barclays upgraded the stock to Overweight in early April, Wells Fargo lifted its target to $31, and several neutral-leaning firms including KBW and Piper Sandler nudged targets higher after the Q1 print. The consensus mean target is $31.33, sitting just above the current price of $30.77 — thin upside for neutral holders but the Raymond James target implies roughly 14% room. The bull case rests on net interest income running at $310 million with margin expansion to 3.06%, deposit growth of 1.9%, and the pending American National acquisition broadening the franchise. Bears flag the 2.3% sequential slide in fee income and a creeping expense base — core costs rose 1.5% — as risks to the efficiency story ahead of Q2. The price-to-book multiple has climbed 10.8 points over the past 30 days to just above 1.0x, and the P/E has moved from roughly 9.0x to 10.1x over the same period, reflecting the stock's 10.6% one-month gain.
The positioning picture is calm rather than charged. Short interest is running at 4.5% of free float — meaningful but not extreme — and has been drifting lower all week, down 2.4% from seven days ago. Borrow is exceptionally cheap at 0.55%, and availability is vast: roughly 4,685% of current short interest, meaning there are more than 130 million shares available to lend against the 7.4 million currently borrowed. That level of availability signals no tension whatsoever in the lending market. Options confirm the relaxed tone: the put/call ratio is 0.20, fractionally below its 20-day average and showing a z-score near zero. There is no sign of hedging activity building into the earnings date.
Insider activity tells a different story from the analyst upgrades. Every transaction recorded in the past 90 days has been a sale, totalling a net $1.7 million of stock offloaded by executives including the General Counsel, Chairman of the Board, and two Executive Vice Presidents. The General Counsel alone sold roughly $845,000 across two tranches in early May at prices around $27.80–$28.30 — well below where the stock trades today. None of the trades involved C-suite principals such as the CEO or CFO, and significance scores were modest across the board, so the pattern reads more as routine diversification than a directional signal. Still, the uniformity of the selling direction into a rising tape is worth noting as the Q2 date approaches.
Peers tracked closely with ASB on the week. FNB gained 1.8%, ONB rose 2.3%, and COLB added 2.5% — all broadly in line with ASB's 3.0% weekly advance. AUB outpaced the group at 4.8%, while ZION lagged at 1.0%. The group move suggests the regional bank bid is sector-wide rather than specific to ASB.
The ORTEX short score is steady at 40, in the lower half of the universe, confirming this is not a name where short-side pressure is a live theme. With Q2 results due July 23, the earnings history shows the stock has dipped modestly on the day — roughly 0.9% to 1.8% in each of the last two prints — before recovering to small gains over the subsequent five sessions. The question for next month is whether the NII trajectory and early signals on the American National integration meet the raised expectations the Street has started to price in.
See the live data behind this article on ORTEX.
Open ASB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
